Boffito M - Search Results

1

Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.

Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back DJ, Khoo S. Marzolini C, et al. Among authors: boffito m. Clin Pharmacol Ther. 2022 Dec;112(6):1191-1200. doi: 10.1002/cpt.2646. Epub 2022 Jun 7. Clin Pharmacol Ther. 2022. PMID: 35567754 Free PMC article. Review.

2

Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment.

Boffito M, Rossati A, Reynolds HE, Hoggard PG, Back DJ, Di Perri G. Boffito M, et al. AIDS Res Hum Retroviruses. 2002 Mar 20;18(5):341-2. doi: 10.1089/088922202753519115. AIDS Res Hum Retroviruses. 2002. PMID: 11897035 No abstract available.

3

The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.

Boffito M, Hoggard PG, Reynolds HE, Bonora S, Meaden ER, Sinicco A, Di Perri G, Back DJ. Boffito M, et al. Br J Clin Pharmacol. 2002 Sep;54(3):262-8. doi: 10.1046/j.1365-2125.2002.01663.x. Br J Clin Pharmacol. 2002. PMID: 12236846 Free PMC article.

4

Simultaneous determination of rifampicin and efavirenz in plasma.

Boffito M, Tija J, Reynolds HE, Hoggard PG, Bonora S, Di Perri G, Back DJ. Boffito M, et al. Ther Drug Monit. 2002 Oct;24(5):670-4. doi: 10.1097/00007691-200210000-00015. Ther Drug Monit. 2002. PMID: 12352941

5

Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics.

Boffito M, Arnaudo I, Raiteri R, Bonora S, Sinicco A, Di Garbo A, Reynolds HE, Hoggard PG, Back DJ, Di Perri G. Boffito M, et al. AIDS. 2002 Oct 18;16(15):2081-3. doi: 10.1097/00002030-200210180-00015. AIDS. 2002. PMID: 12370509

6

Protein binding in antiretroviral therapies.

Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, Miller V. Boffito M, et al. AIDS Res Hum Retroviruses. 2003 Sep;19(9):825-35. doi: 10.1089/088922203769232629. AIDS Res Hum Retroviruses. 2003. PMID: 14585213 Review.

7

Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting.

Boffito M, Bonora S, Sales P, Dal Conte I, Sinicco A, Hoggard PG, Khoo S, Back DJ, Di Perri G. Boffito M, et al. AIDS Res Hum Retroviruses. 2003 Oct;19(10):941-2. doi: 10.1089/088922203322493148. AIDS Res Hum Retroviruses. 2003. PMID: 14585223 No abstract available.

8

Lopinavir protein binding in vivo through the 12-hour dosing interval.

Boffito M, Hoggard PG, Lindup WE, Bonora S, Sinicco A, Khoo SH, Di Perri G, Back DJ. Boffito M, et al. Ther Drug Monit. 2004 Feb;26(1):35-9. doi: 10.1097/00007691-200402000-00008. Ther Drug Monit. 2004. PMID: 14749547 Clinical Trial.

9

Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.

Ford J, Boffito M, Wildfire A, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A. Ford J, et al. Among authors: boffito m. Antimicrob Agents Chemother. 2004 Jul;48(7):2388-93. doi: 10.1128/AAC.48.7.2388-2393.2004. Antimicrob Agents Chemother. 2004. PMID: 15215085 Free PMC article. Clinical Trial.

10

Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.

Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, Higgs C, Fletcher C, Mandalia S, Gazzard B, Pozniak A. Boffito M, et al. Antivir Ther. 2004 Jun;9(3):423-9. Antivir Ther. 2004. PMID: 15259905 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

348 results

Search Page